Feb 18, 2021 · Overview Tukysa is a cancer medicine that is used to treat breast cancer that is locally advanced or metastatic (has spread to other parts of the body) and when it is HER2 …

TUKYSA® (tucatinib), a HER2-directed Rx treatment option for patients with certain HER2-positive cancers. Read full indication and important safety information.

Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. [3][4] It is a small molecule inhibitor of HER2. [6][7] It was …

Jan 14, 2025 · Tukysa (tucatinib) is used for the treatment of patients with HER2-positive breast cancer and RAS wild-type HER2-positive colorectal cancer. Information includes Tukysa side …

Feb 11, 2021 · TUKYSA is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer …

TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast …

Learn about TUKYSA® (tucatinib), a treatment option for certain HER2-positive cancers. See safety info.

TUKYSA is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at …

Nov 8, 2024 · TUKYSA 50 mg film-coated tablets - Summary of Product Characteristics (SmPC) by Pfizer Limited

Apr 3, 2025 · The European Medicines Agency (EMA) has officially authorized Tukysa, a new therapeutic option for patients battling advanced or metastatic HER2-positive breast cancer. …